Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Pharma & Drugs
Share your love
Research supports that iron dysregulation may drive AMD | Ophthalmology Times
Image credit: AdobeStock/Gorodenkoff A new study supports the hypothesis that iron dysregulation may be a driver of dry age-related macular degeneration (AMD). This could be especially true in the early stage of geographic atrophy (GA). According to the research, the…
Bimatoprost drug pad-IOL system shows reduction in mean IOP at 24 months | Ophthalmology Times
Image credit: AdobeStock/oz Interim 24-month data from a trial of the bimatoprost drug pad-IOL system (BIM-IOL system) showed sustained improvements in intraocular pressure (IOP) and visual acuity outcomes.1 The BIM-IOL system has been developed by SpyGlass Pharma, Inc. The company…
Q&A: William F. Wiley, MD, on what BVI’s trifocal IOL approval means for US premium vision options | Ophthalmology Times
The FDA’s approval of the FineVision HP trifocal lens expands the range of premium lens option to US ophthalmologists and their patients. (Image credit: AdobeStock/Margarita Ratatosk) As the landscape of ophthalmic innovation continues to evolve, new technologies are reshaping how…
ICYMI: AAO 2025 showcases new technologies and continued research | Ophthalmology Times
Image credit: AdobeStock/zimmytws The annual scientific meeting of the American Academy of Ophthalmology (AAO) was held in Orlando, Florida. At this meeting, presenters and companies highlighted new technologies and continued areas of research. Ophthalmology Times is highlighting some stories that…
Evolving glaucoma therapy: A new era of interventional strategies | Ophthalmology Times
(Image Credit: AdobeStock/Yakobchuk Olena) Inder Paul Singh, MD, from The Eye Centers of Racine and Kenosha, Wisconsin, recently moderated an Ophthalmology Times Case-Based Roundtable that addressed the new playing field in glaucoma care. For Singh, the term interventional glaucoma no…
Development of maculopathy associated with systemic medications | Ophthalmology Times
Image credit: AdobeStock/James Thew A new study conducted by researchers at Hanyang University, Seoul, Republic of Korea, and the University of North Carolina, Chapel Hill, identified 5 systemic drugs that cause maculopathy that had previously been under-recognized. The researchers, led…
Proactive strategies and sustained delivery advance glaucoma care | Ophthalmology Times
(Image Credit: AdobeStock/Monkey Business) Proactive strategies in glaucoma care, including minimally invasive glaucoma surgery (MIGS) and physician decision-making, were the focus of a recent Ophthalmology Times Case-Based Roundtable, moderated by Sahar Bedrood, MD, PhD, a glaucoma specialist at Advanced Vision…
Novel therapy for incision-free keratoconus: Q&A with Gloria B. Chiu, OD, FAAO, FSLS | Ophthalmology Times
The FDA-approved, incision-free Epioxa therapy is changing the landscape of keratoconus care, explains Gloria B. Chiu, OD, FAAO, FSLS. (Image credit: AdobeStock/Zarina Lukash) Glaukos recently obtained FDA clearance for Epioxa, a topical, incision-free therapy for keratoconus that preserves the corneal epithelium.1 The…
Nanoscope Therapeutics releases positive 3-year follow-up data from REMAIN study | Ophthalmology Times
(Image Credit: AdobeStock/Minerva Studio) Nanoscope Therapeutics has released positive 3-year follow-up data from its REMAIN study, the long-term extension of the phase 2b/3 RESTORE trial (NCT04945772) evaluating MCO-010 in retinitis pigmentosa (RP). RESTORE was a multicenter, randomized, double-masked, sham-controlled, dose-ranging study evaluating 2 dose…
FDA issues Complete Response Letter to Sydnexis for SYD-101 pediatric myopia treatment | Ophthalmology Times
The FDA has requested additional evidence for Sydnexis’ SYD-101, a 0.01% atropine eye drop aimed at slowing myopia progression in children, despite positive outcomes from the STAR clinical trial. (Image credit: Ophthalmology Times) The FDA has sent a complete response…